Acorda Therapeutics Inc (ACOR) Given Average Recommendation of “Hold” by Brokerages

Acorda Therapeutics Inc (NASDAQ:ACOR) has been given an average rating of “Hold” by the eighteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $23.05.

A number of equities research analysts recently weighed in on ACOR shares. HC Wainwright started coverage on Acorda Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $35.00 price target on the stock. Cowen restated a “buy” rating and issued a $30.00 price target on shares of Acorda Therapeutics in a report on Friday, November 17th. TheStreet cut Acorda Therapeutics from a “c-” rating to a “d+” rating in a report on Friday, November 17th. Jefferies Group upped their price target on Acorda Therapeutics from $22.00 to $25.00 and gave the stock a “hold” rating in a report on Wednesday, November 1st. Finally, JPMorgan Chase & Co. set a $24.00 price target on Acorda Therapeutics and gave the stock a “hold” rating in a report on Tuesday, October 31st.

In other news, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $27.58, for a total transaction of $854,980.00. Following the sale, the insider now owns 5,275 shares in the company, valued at $145,484.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the sale, the insider now owns 33,150 shares in the company, valued at approximately $680,569.50. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Meadow Creek Investment Management LLC boosted its holdings in shares of Acorda Therapeutics by 56.0% during the fourth quarter. Meadow Creek Investment Management LLC now owns 8,736 shares of the biopharmaceutical company’s stock worth $187,000 after purchasing an additional 3,136 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Acorda Therapeutics during the third quarter worth $233,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Acorda Therapeutics during the second quarter worth $199,000. Teacher Retirement System of Texas acquired a new stake in shares of Acorda Therapeutics during the fourth quarter worth $347,000. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in shares of Acorda Therapeutics by 59.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 17,510 shares of the biopharmaceutical company’s stock worth $414,000 after purchasing an additional 6,550 shares during the last quarter.

Acorda Therapeutics (ACOR) traded up $0.70 on Wednesday, hitting $25.80. The company had a trading volume of 645,700 shares, compared to its average volume of 796,164. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.81 and a current ratio of 3.07. Acorda Therapeutics has a 1-year low of $13.60 and a 1-year high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.88 by ($0.27). The firm had revenue of $188.40 million during the quarter, compared to analyst estimates of $171.70 million. Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The business’s revenue was up 34.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 EPS. equities research analysts forecast that Acorda Therapeutics will post -0.41 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Acorda Therapeutics Inc (ACOR) Given Average Recommendation of “Hold” by Brokerages” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://ledgergazette.com/2018/02/19/acorda-therapeutics-inc-acor-given-average-recommendation-of-hold-by-brokerages.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply